Clinical Trial Update: SAP Depleter Dose Assessment Study in Patients [Phase 1]

View source ↗

Summary

A Phase 1 dose assessment study of an SAP depleter in patients with amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• SAP Depleter

Snippet

Sponsor: GlaxoSmithKline | Conditions: Amyloidosis | Phase 1 | Status: COMPLETED